(UroToday.com) The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a ...

Please provide your email address to receive an email when new articles are posted on . Black men with prostate cancer had significantly greater odds of having alterations in immunotherapy targets ...

Men with genes that increase the risk of prostate cancer should have annual checks from the age of 40, research has shown.

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

Prostate cancer relies on genetic "switches," called enhancers, that can turn on tumor-promoting genes. Researchers at the ...

For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

They further applied two-sample Mendelian randomization (TSMR) analysis to examine genetic associations between prostate cancer and ten common secondary primary malignancies (SPMs). The study not only ...

Prostate cancer is one of the most common and serious health issues affecting men worldwide. In its early stages, the ...